Lidocaïne de série anesthésique locale de matière première pour le tueur de douleur 137-58-6
Abstrait
CAS:137-58-6
MF:C14H22N2O
MW:234.34
EINECS:205-302-8
Point de fusion:66-69°C
Point d'ébullition:bp4 180-182°; bp2 159-160°
Point d'éclair:9??
température de stockage. Magasin à RT
solubilité éthanol: 4 mg/mL
former de la poudre
color White to slightly yellow
Water Solubility practically insoluble
Merck 14,5482
Stabilité:Stable. Incompatible avec les agents oxydants forts.
La description
Lidocaïne, also known as xylocaine and lignocaine, is a medication used to numb tissue in a specific area and to treat ventricular tachycardia.It can also be used for nerve blocks. Lidocaine mixed with a small amount of epinephrine is available to allow larger doses to be used as numbing and to make it last longer.When used as an injectable, it typically begins working within four minutes and lasts for half an hour to three hours.Lidocaine may also be applied directly to the skin for numbing.
Application
The efficacy profile of lidocaine as a local anesthetic is characterized by a rapid onset of action and intermediate duration of efficacy. Par conséquent, lidocaine is suitable for infiltration, block, and surface anesthesia. Longer-acting substances such as bupivacaine are sometimes given preference for subdural and epidural anesthesias; lidocaine, though, has the advantage of a rapid onset of action. Epinephrine (adrenaline) vasoconstricts arteries, reducing bleeding and also delays the resorption of lidocaine, almost doubling the duration of anaesthesia. For surface anesthesia, several available formulations can be used for endoscopies, before intubations, etc. Buffering the pH of lidocaine makes local numbing less painful. Lidocaine drops can be used on the eyes for short ophthalmic procedures.There is tentative evidence for topical lidocaine for neuropathic pain.
Lidocaine is also the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment ofventricular arrhythmias (pour infarctus aigu du myocarde, empoisonnement à la digoxine, cardioversion, ou cathétérisme cardiaque) si l'amiodarone n'est pas disponible ou est contre-indiquée. La lidocaïne doit être administrée dans cette indication après défibrillation, RCR, and vasopressors have been initiated. A routine preventative dose is no longer recommended after a myocardial infarction as the overall benefit is not convincing.
certificat d'authenticité
Nom du produit |
Lidocaïne |
Apparence |
Poudre cristalline blanche |
Essai (C13H20N2O2·HCl) |
99.0% à 101.0% |
99.5% |
Solution Appearance |
Clear and colorless |
Confirmer |
PH Value |
4.0~5.5 |
4.35 |
Related impurities |
impurity A:≤0.01% |
0.002% |
Single unspecified impurity: ≤0.1% |
0.03% |
Impureté totale: 0,5 % |
0.19% |
Heavy métal |
≤5ppm |
<5ppm |
L'eau |
5.5%~7% |
6.33%
|
Grosses soldes:
Propitocaine hydrochloride |
CAS: 1786-81-8 |
Chlorhydrate de tétracaïne |
CAS: 136-47-0 |
Chlorhydrate de procaïne |
CAS: 51-05-8 |
Chlorhydrate de pramoxine |
CAS: 637-58-1 |
Chlorhydrate de proparacaïne |
CAS: 5875-06-9 |
Chlorhydrate de benzocaïne |
CAS: 23239-88-5 |
Lidocaine hydrochloride |
CAS: 73-78-9 |
Chlorhydrate d'articaïne |
CAS: 23964-57-0 |
Levobupivacaine hydrochloride |
CAS: 27262-48-2 |
Chlorhydrate de ropivacaïne |
CAS: 132112-35-7 |
Dibucaine hydrochloride |
CAS: 61-12-1 |
Bupivacaine hydrochloride |
CAS: 14252-80-3 |
Articaine |
CAS: 23964-58-1 |
Benzocaïne |
CAS: 94-09-7 |
Lidocaïne |
CAS: 137-58-6 |
Tétracaïne |
CAS: 94-24-6 |
PROCAINE |
CAS: 59-46-1 |